


Clinical Trial *IMPACT-DCM*
Presenter - *Timothy Henry, MD*
PI - *Amit Patel, MD*
Sponsor - *Aastrom Biosciences, Inc.*

Target population	VASCULAR, NON-CARDIAC			CARDIAC		
	Critical limb ischemia, Claudication	Atherosclerosis, Restenosis	Pulmonary	Acute MI	Chronic angina	Congestive heart failure 
Progenitor cell, biologic	<i>Autologous Bone marrow derived</i>					
Delivery method	<i>Surgical Intramyocardial injection</i>					
Study Phase	<i>2</i>					
Primary objective	<i>Safety</i>					
Design	<i>+ Randomized, + Controlled (std of care), - Placebo</i>					
# Clinical sites	<i>5</i>					
www.ClinTrials.gov	<i>NCT00765518</i>					

Clinical Trial - *IMPACT-DCM*
Target enrollment - *40*
Start date, End date *September 2008, February 2012*

Study Flow and Current Enrollment

40 enrolled

+ Randomized

Day 0

ixmyelocel-T (25)

Std of Care Control (15)

Month 12

21 Patients

7 Patients

1° safety

Month 24

Patients

Patients

MACE follow-up

Status: **Enrollment completed**